Literature DB >> 25422269

Impact of the glpQ2 gene on virulence in a Streptococcus pneumoniae serotype 19A sequence type 320 strain.

Yi-Ping Chuang1, Zih-Rong Peng2, Shun-Fu Tseng3, Yu-Chun Lin4, Huey-Kang Sytwu2, Yu-Chia Hsieh5.   

Abstract

Glycerophosphodiester phosphodiesterase (GlpQ) metabolizes glycerophosphorylcholine from the lung epithelium to produce free choline, which is transformed into phosphorylcholine and presented on the surfaces of many respiratory pathogens. Two orthologs of glpQ genes are found in Streptococcus pneumoniae: glpQ, with a membrane motif, is widespread in pneumococci, whereas glpQ2, which shares high similarity with glpQ in Haemophilus influenzae and Mycoplasma pneumoniae, is present only in S. pneumoniae serotype 3, 6B, 19A, and 19F strains. Recently, serotype 19A has emerged as an epidemiological etiology associated with invasive pneumococcal diseases. Thus, we investigated the pathophysiological role of glpQ2 in a serotype 19A sequence type 320 (19AST320) strain, which was the prevalent sequence type in 19A associated with severe pneumonia and invasive pneumococcal disease in pediatric patients. Mutations in glpQ2 reduced phosphorylcholine expression and the anchorage of choline-binding proteins to the pneumococcal surface during the exponential phase, where the mutants exhibited reduced autolysis and lower natural transformation abilities than the parent strain. The deletion of glpQ2 also decreased the adherence and cytotoxicity to human lung epithelial cell lines, whereas these functions were indistinguishable from those of the wild type in complementation strains. In a murine respiratory tract infection model, glpQ2 was important for nasopharynx and lung colonization. Furthermore, infection with a glpQ2 mutant decreased the severity of pneumonia compared with the parent strain, and glpQ2 gene complementation restored the inflammation level. Therefore, glpQ2 enhances surface phosphorylcholine expression in S. pneumoniae 19AST320 during the exponential phase, which contributes to the severity of pneumonia by promoting adherence and host cell cytotoxicity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25422269      PMCID: PMC4294258          DOI: 10.1128/IAI.02357-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  64 in total

1.  Streptococcus pneumoniae--associated hemolytic uremic syndrome: classification and the emergence of serotype 19A.

Authors:  Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatrics       Date:  2009-12-21       Impact factor: 7.124

2.  Necrotizing pneumococcal pneumonia with bronchopleural fistula among children in Taiwan.

Authors:  Yu Chia Hsieh; Chih-Wei Wang; Shen-Hao Lai; Jin-Yao Lai; Kin-Sun Wong; Yhu-Chering Huang; Kuang-Yi Chang; Cheng-Hsun Chiu; Tzou-Yien Lin
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

Review 3.  Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease.

Authors:  Federico Iovino; Matthijs C Brouwer; Diederik van de Beek; Grietje Molema; Jetta J E Bijlsma
Journal:  Cell Microbiol       Date:  2013-03-20       Impact factor: 3.715

4.  The choline-binding protein PspC of Streptococcus pneumoniae interacts with the C-terminal heparin-binding domain of vitronectin.

Authors:  Sylvia Voss; Teresia Hallström; Malek Saleh; Gerhard Burchhardt; Thomas Pribyl; Birendra Singh; Kristian Riesbeck; Peter F Zipfel; Sven Hammerschmidt
Journal:  J Biol Chem       Date:  2013-04-19       Impact factor: 5.157

5.  Enolase of Streptococcus pneumoniae binds human complement inhibitor C4b-binding protein and contributes to complement evasion.

Authors:  Vaibhav Agarwal; Sven Hammerschmidt; Sven Malm; Simone Bergmann; Kristian Riesbeck; Anna M Blom
Journal:  J Immunol       Date:  2012-08-27       Impact factor: 5.422

6.  Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.

Authors:  Reshmi Mukerji; Shaper Mirza; Aoife M Roche; Rebecca W Widener; Christina M Croney; Dong-Kwon Rhee; Jeffrey N Weiser; Alexander J Szalai; David E Briles
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

7.  Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population.

Authors:  Ron Dagan; Noga Givon-Lavi; Eugene Leibovitz; David Greenberg; Nurith Porat
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

8.  Pneumococcal serotypes causing acute otitis media among children in Barcelona (1992-2011): emergence of the multiresistant clone ST320 of serotype 19A.

Authors:  Amadeu Gene; Eva del Amo; Melania Iñigo; Manuel Monsonis; Roman Pallares; Carmen Muñoz-Almagro
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

9.  A trigger enzyme in Mycoplasma pneumoniae: impact of the glycerophosphodiesterase GlpQ on virulence and gene expression.

Authors:  Sebastian R Schmidl; Andreas Otto; Maria Lluch-Senar; Jaume Piñol; Julia Busse; Dörte Becher; Jörg Stülke
Journal:  PLoS Pathog       Date:  2011-09-22       Impact factor: 6.823

10.  Fosfomycin suppresses RS-virus-induced Streptococcus pneumoniae and Haemophilus influenzae adhesion to respiratory epithelial cells via the platelet-activating factor receptor.

Authors:  Shin-ichi Yokota; Tamaki Okabayashi; Yuko Yoto; Tsukasa Hori; Hiroyuki Tsutsumi; Nobuhiro Fujii
Journal:  FEMS Microbiol Lett       Date:  2010-06-28       Impact factor: 2.742

View more
  1 in total

1.  Identification of extracellular glycerophosphodiesterases in Pseudomonas and their role in soil organic phosphorus remineralisation.

Authors:  Ian D E A Lidbury; Andrew R J Murphy; Tandra D Fraser; Gary D Bending; Alexandra M E Jones; Jonathan D Moore; Andrew Goodall; Mark Tibbett; John P Hammond; David J Scanlan; Elizabeth M H Wellington
Journal:  Sci Rep       Date:  2017-05-19       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.